Respiratory syncytial virus monoclonal antibodies: A bibliometric and visual analysis
This study presents the first comprehensive bibliometric analysis of Respiratory Syncytial Virus monoclonal antibody research, revealing a post-2021 surge in publications and a paradigm shift toward nirsevimab and universal infant protection, while highlighting the critical disparity between the high disease burden in low- and middle-income countries and their minimal research contribution and access to these therapies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, a common virus known as respiratory syncytial virus, or RSV, sweeps through communities, causing severe breathing difficulties for infants and young children. While most adults and older children shrug off the infection with a simple cold, it can be dangerous for the very young, leading to pneumonia and hospitalization. For decades, the medical world has relied on a strategy called passive immunization to protect the most vulnerable babies. Instead of waiting for a child's own immune system to learn how to fight the virus—a process that takes time and often fails in newborns—doctors can give these infants a direct dose of antibodies. Think of it as lending a child a shield they cannot yet make for themselves. These antibodies act immediately, neutralizing the virus before it can cause serious harm. For a long time, the only available shield was a medication that required a series of monthly injections during the cold and flu season, a regimen that was difficult for families to manage and limited to only the highest-risk infants.
A new study by researchers at Capital Medical University and Beijing Children's Hospital has taken a fresh look at the entire global effort to improve these treatments. The team did not run new clinical trials or test new drugs in a laboratory. Instead, they performed a large-scale map of the scientific literature, a method known as bibliometric analysis. They gathered thousands of research papers published over the last few decades to see how the field has grown, who is leading the work, and where the focus of scientific attention has shifted. By analyzing patterns in publication dates, author names, and the topics researchers discuss, they constructed a clear picture of how the fight against RSV has evolved from a niche concern for a few sick children into a major global health priority.
The researchers found that the field has been changing rapidly, particularly since 2021. For many years, the number of new studies remained relatively steady, focused on refining the use of an older medication called palivizumab. This drug was effective but required monthly shots and was reserved for infants with serious heart or lung conditions. However, the data shows an explosion in research activity starting in 2021, with the number of published papers surging to nearly 200 in 2025 alone. This sudden growth coincides with the arrival of a new generation of antibodies, most notably a drug called nirsevimab. Unlike its predecessor, this new treatment is designed to last much longer, often providing protection for an entire season with a single injection. This shift has allowed scientists to move beyond protecting only the sickest children and has opened the door to protecting all healthy infants, a strategy known as universal protection.
The study also revealed who is driving this progress. The United States leads the world in the number of research papers produced, followed by several European nations. The most productive single organization in this field is not a university or a government agency, but a pharmaceutical company, AstraZeneca, which has published more papers on the topic than any other institution. This highlights the critical role of industry in developing these complex medicines. The research community has also formed tight networks, with scientists in the US, UK, Netherlands, Spain, and Canada working closely together. However, the map of global research shows a stark imbalance. While low- and middle-income countries suffer the vast majority of RSV-related deaths, they contribute very little to the scientific research that leads to new treatments. This gap means that the countries that need these life-saving medicines the most are often the least equipped to access them or to participate in the studies that prove they work.
Looking at the specific topics scientists are studying, the focus has moved decisively away from the old monthly shots and toward the new long-acting antibodies. The most prominent keywords in recent years include "nirsevimab," "preterm infants," and "maternal immunization." Researchers are now deeply interested in how well these new drugs work in the real world, not just in controlled trials, and how they compare to vaccines given to pregnant mothers to protect their babies. The data suggests that the new long-acting antibodies are superior to the older options because they are easier to administer and can protect a much wider group of children. The study also notes that while the science is advancing quickly, the high cost of these new treatments remains a significant barrier. The researchers conclude that while the scientific community has made remarkable strides in understanding how to protect infants from RSV, true success will depend on global cooperation to ensure that these life-saving tools reach the children who need them most, regardless of where they are born.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.